Indian drugmaker Dr. Reddy’s to launch generic Ozempic
The landscape of diabetes treatment in India is poised for significant change. Dr. Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s Ozempic in March, coinciding with the expiration of the drug’s patent in India. This move has the potential to dramatically increase access to care and intensify competition within the rapidly expanding market for both diabetes and weight-loss medications.
A New Era of Affordability
Dr. Reddy’s Laboratories Ltd. intends to price its generic Ozempic competitively, with a stated goal of improving affordability for Indian patients living with type 2 diabetes. M.V. Ramana, CEO for Branded Markets, indicated that pricing will be determined by market conditions and the actions of competitors, calling the situation “a major opportunity.”
Investor Confidence
Financial markets reacted positively to the news. Shares of Dr. Reddy’s jumped as much as 5.8% in Mumbai on Thursday, marking the largest single-day increase since April. This surge followed a strong performance in the December quarter, exceeding analyst expectations.
Global Expansion Plans
India represents a key strategic market for Dr. Reddy’s, but the company’s ambitions extend beyond its borders. CEO Erez Israeli highlighted potential opportunities in Turkey, Brazil, and Canada.
Analysts anticipate a substantial decrease in prices as generic versions of Ozempic, which contains the key ingredient semaglutide, become available. Nomura analyst Saion Mukherjee estimates that generic semaglutide could cost as little as $40 by 2026, less than half of the current price in India.
Increased Access and Supply
Lower prices could broaden access to treatment beyond major urban centers, potentially leading to more frequent prescriptions and improved patient adherence. Dr. Reddy’s plans to distribute 12 million pens in the first year, and will manufacture the active pharmaceutical ingredient internally to control costs and ensure a consistent supply.
To expand its reach, Dr. Reddy’s will collaborate with other Indian companies for marketing and distribution. The company has already received both marketing and manufacturing approvals from the Drugs Controller General of India, allowing for a swift launch upon patent expiration.
Beyond Ozempic: Wegovy and Canada
Dr. Reddy’s is also seeking approval in India for a non-branded version of Wegovy, Novo Nordisk’s weight-loss drug, and awaits a marketing decision.
Canada is another key focus for the company. In November, Dr. Reddy’s responded to a notice of non-compliance from Health Canada regarding regulatory requirements. A decision from Health Canada is expected by May, and Israeli stated the company is prepared to launch immediately if approved, potentially becoming the first to market in Canada.
Frequently Asked Questions
What is Dr. Reddy’s plan regarding Ozempic?
Dr. Reddy’s Laboratories plans to launch a generic version of Novo Nordisk’s Ozempic in India in March, following the expiration of the drug’s patent on March 21.
What impact could this have on drug prices?
Analysts expect prices for semaglutide, the active ingredient in Ozempic and Wegovy, to decrease significantly as generic versions enter the market, potentially falling to as low as $40 by 2026.
Is Dr. Reddy’s focusing solely on India?
No, Dr. Reddy’s also sees strong potential in markets such as Turkey, Brazil, and Canada, and is actively pursuing approvals and addressing regulatory concerns in those regions.
As generic competition increases and access expands, will these changes ultimately improve health outcomes for individuals managing diabetes and related conditions?